139 results about "Endothelial Cell Growth Factor" patented technology

The invention concerns the prevention and treatment of endothelial injury and the injury of tissues containing injured blood vessels by administration of angiogenic factors, such as vascular endothelial cell growth factor (VEGF).

The invention discloses a preparation method of an essence containing human mesenchymal stem cell factors. The preparation method of the essence containing the human mesenchymal stem cell factors comprises the steps: preparation of freeze-dried powder of the human mesenchymal stem cell factors, preparation of a solvent and mixing. The preparation method obtains a high-purity and high-activity stem cell active factor concentrated solution by a cryoconcentration technique and the concentrated solution is freeze-dried to obtainfreeze-dried powder at low temperature in vacuum, so that the factor activity can be kept for a long time; and the solvent contains multiple skin nourishing and moisturizing components and a stem cell lysis solution, can well dissolve the cell factor freeze-dried powder and keeps the cell factor activity. The stem cell essence disclosed by the invention contains vascular endothelial cell growth factors, platelet derived growth factors, epidermal growth factors and other components, can promote skin regeneration, can play roles in moisturizing, tendering, whitening and repairing the skin, and has good application prospects in fields of medical beauty treatment, health protection and the like.

The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.

A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial cell growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.

The present invention involves the preparation of vascular endothelial growth actor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.

The invention belongs to the technical field of genetic engineering antibodies and particularly relates to a whole human source single chain antibody which is designed and expressed by genetic engineering and has specific affinity towards human vascular endothelial growth factor receptor 2 (VEGFR-2). The invention also provides a nucleotide sequence of heavy chain variable region and light chain variable region immunoglobulin molecules, a nucleotide sequence which comprises the heavy chain variable region and light chain variable region immunoglobulin molecules, an amino acid sequence which comprises variable heavy chain and variable light chain immunoglobulin molecules, and a sequence which corresponds to CDR1, CDR2 and CDR3 of a complementary determining region. The invention also provides a method for generating and expressing the anti-VEGFR-2 single chain antibody, by cycling operations of gathering-elution-gathering, an antibody which has specific affinity towards the human vascular endothelial growth factor is screened, and then the single chain antibody is obtained through a prokaryotic cell secretion and expression system and an affinity purification system. The antibody can be coupled with a detectable substance and therapeutic agent.

The invention belongs to the field of biotechnology-monoclonal antibody. The present invention discloses a monoclonal antibody for antagonistic inhibition of combination of vascular endothelial cell growth factor (VEGF) and a receptor of the VEGF, and a hybridoma cell line secreting the monoclonal antibody, wherein the preservation number of the hybridoma cell line is CGMCC No.5889. The present invention further discloses a preparation method and a use of the monoclonal antibody, wherein the use comprises application of the monoclonal antibody in VEGF protein detection and application of the monoclonal antibody in preparation of a drug preparation for treatment of angiogenesis-related diseases.

The invention discloses a preparation method of a surface coating of intravascular stents or cardiac valves with excellent biocompatibility, which includes the steps: A. the preparation of a coating solvent: heparin is dissolved in deionized water, the pH value thereof is adjusted to 7 to 8 and then an endothelial cell growth factor is added to form a heparin/growth factor solution; collagens are dissolved in acetum to form a collagen solution; B. dip-coating: the intravascular stents or the cardiac valves are immersed in the heparin/growth factor solution and a layer of heparin/growth factor is dipped and coated on the surface of the intravascular stents or the cardiac valves, and then the intravascular stents or the cardiac valves are taken out for being cleaned by the deionized water and being dried by nitrogen gas; and the intravascular stents or the cardiac valves are immersed in the collagen solution, coated with a layer of collagen, and taken out for being cleaned by the deionized water and being dried by nitrogen gas; the steps of dip-coating by the use of the heparin/growth factor and the collagen are repeated in sequence for 1 time to 60 times; finally the step of dip-coating by the use of the heparin/growth factor is carried out again to obtain the surface coating with excellent biocompatibility of the intravascular stents or the cardiac valves. The intravascular stents or the cardiac valves prepared have excellent biocompatibility and low preparation cost.

The invention discloses an inhibition method for induced differentiation of hair follicle stem cells into vascular endothelial cells, comprising: (1), isolating rat hair follicle stem cell; (2), culturing the rat hair follicle stem cells; (3), purifying the rat hair follicle stem cells; (4), inhibiting the induced differentiation of the rat hair follicle stem cells into vascular endothelial cells. In the inhibition method provided herein, vascular endothelial cell growth factor 165 is used for the first time as an inducing factor so that the rat hair follicle stem cells efficiently and directionally differentiate into vascular endothelial cells; the formation and growth of vascular endothelial cells generated by induced differentiation of the hair follicle stem cells can be adjusted, an effective healing of a wound is promoted; it is also possible to provide seed cell sources for solving the problems in vascularization of tissue engineering skin, cell-transplant therapy of ischemic disease and the like.

The invention relates to a method for preparing an in-situ tissue engineering blood vessel by a composite process. According to the invention, a three-layer composite intravascular stent which is similar to a natural vascular structure and is used for in-situ tissue engineering is prepared by combining rapid prototyping, electrostatic spinning and wet spinning processes; wherein the inner layer isa tubular stent provided with an axial groove by utilizing 3D printing and electrostatic spinning technologies; a middle layer is a tubular stent which is prepared by wet spinning and is provided with circumferentially arranged fibers; and the outer layer is the tubular stent which is prepared by the coatable inner layer obtained by electrostatic spinning and the disordered fibers at the middle layer. Through heparinization, the vascular endothelial cell growth factor is loaded, so that cells can be collected in a host, the infection opportunity of in-vitro culture is reduced, the preparationof in-situ tissue engineering blood vessels is realized, and the method has a wide prospect in the field of tissue engineering blood vessels.

The invention discloses a nerve repairing material and a preparation method thereof. The nerve repairing material comprises a combination of cell factors capable of promoting nerve growth, and a controlled-release carrier of the cell factors, wherein the carrier is mainly composed of fibrinogen, fibronectin, heparin, fibrin stabilizing factor, thrombin and calcium chloride, wherein the combination of the cell factors capable of promoting nerve growth is optimally at least two of nerve growth factor, brain-derived neurotrophic factor, basic fibroblast growth factor and vascular endothelial cell growth factor, and is embedded in the carrier. According to the nerve repairing material, the speed of releasing cell factors can be regulated according to the nerve repairing progress by utilizing 'intelligent release' of the controlled-release carrier, so that the functions of cell factors can be progressively played; furthermore, the nerve repairing can be further promoted by utilizing the synergy of the cell factors.

The invention discloses a mimic short peptide 7B of endothelial cell growth factor VEGF antigen epitope and an application thereof. The amino acid sequence of the mimic short peptide 7B is FKPSCVPLMRCGGCCN and the nucleotide sequence is TTCAAACCGTCCTGCGTTCCGCTGATGCGTTGCGGTGGTTGTGCAACG. In vitro experiments show that the mimic short peptide 7B of the invention has obvious inhibiting effect during the processes of endothelial cell proliferation and tube formation and the tumor cell proliferation and migration. Therefore, the mimic short peptide 7B of the invention can be used for preparing peptide vaccines, tumor angiogenesis inhibitor or tumor-oriented drugs, and has great reference value on diagnosing and predicting tumorigenesis by utilizing VEGF receptor as a target, discussing development of small molecular peptides on the tumor angiogenesis inhibitors, and developing and researching tumor-oriented drugs.

The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

The invention belongs to the field of biotechnology and provides a stem cell induced culture solution used for eyes .The stem cell induced culture solution comprises a vascular endothelial cell growth factor (VEGF), a basic fibroblast growth factor (bFGF) and an epidermal growth factor (EGF); the content of the vascular endothelial cell growth factor (VEGF) is 0.5-2.5 ng/ml, the content of the basic fibroblast growth factor (bFGF) is 0.25-0.4 ng/ml, and the content of the epidermal growth factor (EGF) is 0.5-2.0 ng/ml .The stem cell (ASCs) in vitro conditioned culture medium from human eyepit fat is adopted, and a significant reinforcement function is achieved for regeneration and repair of corneal injury.

This invention relates to a fusion protein that possess action of selectively kill tumour rebirth blood vessel endotheliocyte, and its application. This fusion protein through connecting peptide connect VEGF121 with amido end of sponge gourd seed ribosome inactivating protein(RIP) Luffin Alpha. The vascular endothelial cell growth factor VEGF121 act as means of delivery, make this fusion toxin idiosyncratic incorporate with vascular endothelial cell growth factor receptor F1k1/ KDR, thereby optionally ingress tumour rebirth vascular endothelial cell; the polypeptide possess amphipathic molecule character, by destroy lysosome membrane to promote the release of lysosome inside dissociate toxin molecule; the toxin carboxyl terminal endoplasmic reticulum loacting signal led toxin molecule( sponge gourd seed RIP Luffin Alpha) to target site to exert toxic effect, so to destroy rebirth blood vessel of tumour organization, cut off tumour blood supply, achieve the end of restraining tumor.

The invention discloses a cryoprotectant for umbilical cord mesenchymal stem cells and application of the cryoprotectant. The cryoprotectant comprises a human serum albumin solution, a dimethyl sulfoxide solution, trophic factors and a pharmaceutically-acceptable carrier, and the trophic factors are one or more of a vascular endothelial cell growth factor VEGF, a transforming growth factor TGF, interleukin 6IL-6, a fiber bud cell growth factor bFGF and a hepatocyte growth factor HGF. The invention discloses the application of the cryoprotectant for the umbilical cord mesenchymal stem cells incryopreservation of the umbilical cord mesenchymal stem cells. Through the above mode, according to the application, the specific cryoprotectant is adopted to cryopreserve the umbilical cord mesenchymal stem cells, allows the cryopreserved umbilical cord mesenchymal stem cells to keep activity and differentiation stemness, and has a good cryopreservation effect.

The invention discloses bifidobacterium bifidum NX-7 and application of NX-7 in preparation of a medicine for treating ischemic diseases, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium bifidum NX-7 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 20115. The inactivated and non-inactivated fermentation supernatant and bacterial suspension of the bifidobacterium bifidum NX-7 can significantly promote the growth of the zebra fish subintestinal veins in vivo, significantly repair the injury of the zebra fish subintestinal veins induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), significantly promote the repair of the injury of the zebra fish tail fin, has the potential of promoting microcirculation regeneration and reconstruction, and shows the effect of being applied to in-vivo treatment of ischemic diseases. The bifidobacterium bifidum NX-7 disclosed by the invention has a huge potential application prospect in the aspect of treating ischemic diseases.

The invention relates to a method for preparing a cartilage angiogenesis inhibiting factor for a scalloped hammerhead shark. During preparation, Pro-Asp-Tyr-Lys-Phe-Lys is obtained through cartilage homogenate of the scalloped hammerhead shark, guanidine hydrochloride extraction, acetone precipitation and grading, enzymolysis, gel filtration chromatography, cell membrane chromatography purification and efficient liquid phase chromatography purification. The angiogenesis inhibiting factor can effectively inhibit angiogenesis of chick chorioallantoic membranes, and has an obvious inhibition function on expression of three angiogenesis promoting factors including the vascular endothelial cell growth factor, the basic fibroblast growth factor and the platelet-derived growth factor of lung cancer tissue of mice suffering from the Lewis lung cancer.